A detailed history of Amalgamated Bank transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 2,499 shares of KURA stock, worth $22,341. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,499
Previous 2,499 -0.0%
Holding current value
$22,341
Previous $51,000 3.92%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$17.53 - $22.98 $1,753 - $2,298
100 Added 4.17%
2,499 $51,000
Q1 2024

Apr 23, 2024

SELL
$13.42 - $23.53 $50,499 - $88,543
-3,763 Reduced 61.07%
2,399 $51,000
Q4 2023

Feb 06, 2024

SELL
$7.58 - $14.38 $5,017 - $9,519
-662 Reduced 9.7%
6,162 $89,000
Q3 2023

Nov 08, 2023

BUY
$8.44 - $11.86 $3,806 - $5,348
451 Added 7.08%
6,824 $62,000
Q2 2023

Aug 11, 2023

SELL
$9.62 - $13.99 $4,781 - $6,953
-497 Reduced 7.23%
6,373 $67,000
Q1 2023

May 02, 2023

SELL
$10.71 - $14.6 $15,732 - $21,447
-1,469 Reduced 17.62%
6,870 $84,000
Q4 2022

Feb 10, 2023

BUY
$11.23 - $16.9 $2,740 - $4,123
244 Added 3.01%
8,339 $103,000
Q3 2022

Nov 09, 2022

BUY
$12.01 - $19.45 $948 - $1,536
79 Added 0.99%
8,095 $111,000
Q2 2022

Aug 15, 2022

BUY
$10.71 - $18.33 $3,919 - $6,708
366 Added 4.78%
8,016 $147,000
Q1 2022

Jun 30, 2022

BUY
$11.78 - $16.98 $90,117 - $129,897
7,650 New
7,650 $123,000
Q2 2021

Aug 16, 2021

SELL
$20.85 - $29.88 $184,126 - $263,870
-8,831 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$24.75 - $39.14 $17,919 - $28,337
-724 Reduced 7.58%
8,831 $250,000
Q4 2020

Feb 12, 2021

BUY
$29.0 - $41.62 $37,845 - $54,314
1,305 Added 15.82%
9,555 $312,000
Q3 2020

Oct 30, 2020

BUY
$16.3 - $30.64 $134,475 - $252,780
8,250 New
8,250 $253,000

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $598M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.